Dementia praecox ou Groupe des schizophr. nies. Paris, 1993. ,
Schizophre?nie: diagnostic et prise en charge. Issy-les-Moulineaux, 2013. ,
Pharmacologie et mode d'action des neuroleptiques. EMC - Psychiatr, pp.282-99, 2005. ,
DOI : 10.1016/s0246-1072(05)32572-7
Psychopathologie de l'adulte. Issy-les-Moulineaux, 2010. ,
Available from, SCHIZOPHRÉNIES [Internet], 2007. ,
DSM-IV-TR manuel diagnostique et statistique des troubles mentaux, 2004. ,
La schizophre?nie de l'adulte: des causes aux traitements, 2006. ,
Dossiers d'information schizophrenie [Internet]. 2014 Available from: http://www.inserm.fr/thematiques/neurosciences-sciences-cognitives-neurologie- psychiatrie/dossiers-d-information/schizophrenie ,
La reme?diation cognitive : un nouvel outil de soin pour la schizophrénie. Perspect Psy, pp.7-13, 2012. ,
DOI : 10.1051/ppsy/2011511007
One hundred years of schizophrenia: A meta-analysis of the outcome literature, Schizophrenia Research, vol.9, issue.2-3, 1994. ,
DOI : 10.1016/0920-9964(93)90221-4
Manuel de psychiatrie clinique et psychopathologique de l'adulte. Paris: Puf; 2012 ,
Traduction des recommandations pour le traitement biologique des schizophre?nies Chapitre I : traitement de la phase aiguë [Internet]. The World Federation of Societies of Biological Psychiatry (WFSBP); Available from ,
History, aetiology, and symptomatology of schizophrenia, Psychiatry, vol.7, issue.10, pp.404-413, 2008. ,
DOI : 10.1016/j.mppsy.2008.07.010
The Genetics of Mental Disorder, 1971. ,
Fondation des maladies mentales Available from ,
Available from: http://www.psychologies.com/Dico-Psycho/Antipsychotique 24, 2014. ,
Schizophre?nie : prise en charge [Internet] Available from ,
The evolution of drug development in schizophrenia: past issues and future opportunities. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol, pp.2061-79, 2008. ,
Les neuroleptiques [Internet] Universite?deUniversite?de Poitiers : faculte?defaculte?de me?decine Available from: http://www.schizophrenies.fr/PDF/SENON_CSCT_neuroleptiques.pdf 29, La Commission européenne approuve le XEPLION(R) pour le traitement de la schizophrénie [Internet], 2002. ,
Amphetamine psychosis monographs, Maudsley, issue.5, 1958. ,
Building a better antipsychotic: Receptor targets for the treatment of multiple symptom dimensions of schizophrenia, Neurotherapeutics, vol.100, issue.1, pp.78-85, 2009. ,
DOI : 10.1073/pnas.1835612100
The Nature of Dopamine Dysfunction in Schizophrenia and What This Means for Treatment, Archives of General Psychiatry, vol.69, issue.8, 2009. ,
DOI : 10.1001/archgenpsychiatry.2012.169
Depletion in serotonin decreases neurogenesis in the dentate gyrus and the subventricular zone of adult rats, Neuroscience, vol.89, issue.4, pp.999-1002, 1999. ,
DOI : 10.1016/S0306-4522(98)00693-9
The role of serotonin receptors in the action of atypical antipsychotic drugs, Current Opinion in Pharmacology, vol.11, issue.1, pp.59-67, 2011. ,
DOI : 10.1016/j.coph.2011.02.007
Available from, 2006. ,
Antipsychotic drug doses and neuroleptic/dopamine receptors, Nature, vol.16, issue.5562, pp.717-726, 1976. ,
DOI : 10.1002/cpt1972136931
Use of atypical antipsychotics in Charles Perrens psychiatric hospital (Bordeaux) analysis of prescribing practices for, pp.329-371, 2002. ,
Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial, The Lancet, vol.371, issue.9618, pp.1085-97, 2008. ,
DOI : 10.1016/S0140-6736(08)60486-9
Efficacy of Metformin and Topiramate in Prevention and Treatment of Second-Generation Antipsychotic-Induced Weight Gain ,
Incidence of Newly Diagnosed Diabetes Attributable to Atypical Antipsychotic Medications, American Journal of Psychiatry, vol.161, issue.9, pp.1709-1720, 2004. ,
DOI : 10.1176/appi.ajp.161.9.1709
Les effets indésirables des neuroleptiques ,
Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease, New England Journal of Medicine, vol.355, issue.15, pp.1525-1563, 2006. ,
DOI : 10.1056/NEJMoa061240
Metabolic Changes Associated With Second-Generation Antipsychotic Use in Alzheimer???s Disease Patients: The CATIE-AD Study, American Journal of Psychiatry, vol.166, issue.5, pp.583-90, 2009. ,
DOI : 10.1176/appi.ajp.2008.08081218
Force on Treatment Guidelines for Schizophrenia traduction française par H. Verdoux, Recommandations pour le traitement biologique de la Schizophrénie Partie 2: Traitement à long terme de la Schizophrénie [Internet]. Available from ,
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis, The Lancet, vol.373, issue.9657, 2009. ,
DOI : 10.1016/S0140-6736(08)61764-X
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia, New England Journal of Medicine, vol.353, issue.12, pp.1209-1232, 2005. ,
DOI : 10.1056/NEJMoa051688
Randomized Controlled Trial of the Effect on Quality of Life of Second- vs First-Generation Antipsychotic Drugs in Schizophrenia, Archives of General Psychiatry, vol.63, issue.10, pp.1079-87, 2006. ,
DOI : 10.1001/archpsyc.63.10.1079
Randomized controlled trial of effect of prescription of clozapine versus other secondgeneration antipsychotic drugs in resistant schizophrenia, Schizophr Bull, 2006. ,
A Meta-Analysis of Head-to-Head Comparisons of Second-Generation Antipsychotics in the Treatment of Schizophrenia, American Journal of Psychiatry, vol.166, issue.2, pp.152-63, 2009. ,
DOI : 10.1176/appi.ajp.2008.08030368
The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements, Schizophrenia Bulletin, vol.57, issue.8, pp.71-93, 2010. ,
DOI : 10.1176/appi.ps.57.8.1094
Increasing offlabel use of antipsychotic medications in the United States, 1995. ,
Stimulation magnétique transcranienne répétée (rTMS) en psychiatrie : situation actuelle et perspectives ,
Schizophrénie [Internet]. 2012 Available from ,
La re?e?ducation cognitive : e?valuation des re?sultats, Revue française des affaires sociales, pp.1-2, 2009. ,
Effectiveness of Integrated Psychological Therapy (IPT) for Schizophrenia Patients: A Research Update, Schizophrenia Bulletin, vol.19, issue.5, pp.71-79, 2011. ,
DOI : 10.1177/1049731509335561
Specific cognitive flexibility rehabilitation in schizophrenia, Psychological Medicine, vol.38, issue.01, pp.221-228, 1993. ,
DOI : 10.1192/bjp.157.1.50
Cognitive Behavior Therapy for Schizophrenia: Effect Sizes, Clinical Models, and Methodological Rigor, Schizophrenia Bulletin, vol.34, issue.3, 2008. ,
DOI : 10.1093/schbul/sbm114
Proof of Concept: A PhRMA Position Paper With Recommendations for Best Practice. Clin Pharmacol 38 Ther, pp.278-85, 2010. ,
Placebo : De?finitions, inte?rêt, utilisation Master 2 pro : Pharmacologie et métiers du médicament, 2014. ,
The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery, Schizophrenia Research, vol.68, issue.2-3, pp.2-3283, 2004. ,
DOI : 10.1016/j.schres.2003.09.011
Inte?rêt d'un nouvel instrument dans l'e?valuation cognitive dans la schizophre?nie. L'Ence?phale, 2008. ,
DOI : 10.1016/j.encep.2007.12.005
Computerised cognitive assessment of concussed Australian Rules footballers, British Journal of Sports Medicine, vol.35, issue.5, 2001. ,
DOI : 10.1136/bjsm.35.5.354
A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic schizophrenia, Journal of Clinical and Experimental Neuropsychology, vol.27, issue.7, pp.848-59, 2009. ,
DOI : 10.1016/j.neuropsychologia.2008.04.010
Validity of the CogState Brief Battery: Relationship to Standardized Tests and Sensitivity to Cognitive Impairment in Mild Traumatic Brain Injury, Schizophrenia, and AIDS Dementia Complex, Archives of Clinical Neuropsychology, vol.16, issue.7, pp.165-78, 2009. ,
DOI : 10.1093/arclin/16.7.653
Using the Cambridge Neuropsychological Test Automated Battery (CANTAB) to assess the cognitive impact of electroconvulsive therapy on visual and visuospatial memory, Psychological Medicine, vol.3, issue.06, pp.1017-1042, 2010. ,
DOI : 10.1080/01688638608405179
Interview-based assessment of cognition in schizophrenia: Applicability of the Schizophrenia Cognition Rating Scale (SCoRS) in different phases of illness and settings of care, Schizophrenia Research, vol.146, issue.1-3, pp.217-240, 2013. ,
DOI : 10.1016/j.schres.2013.02.035
UCSD Performance-Based Skills Assessment: Development of a New Measure of Everyday Functioning for Severely Mentally Ill Adults, Schizophrenia Bulletin, vol.27, issue.2, pp.235-280, 2001. ,
DOI : 10.1093/oxfordjournals.schbul.a006870
Usefulness of the UCSD performance-based skills assessment (UPSA) for predicting residential independence in patients with chronic schizophrenia, Journal of Psychiatric Research, vol.42, issue.4, 2008. ,
DOI : 10.1016/j.jpsychires.2006.12.008
Cynthia Siu e, Antony Loebel Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial, Schizophrenia Research, vol.125, pp.161-168, 2011. ,
Systematic review of appropriate cognitive assessment instruments used in clinical trials of schizophrenia, major depressive disorder and bipolar disorder, Psychiatry Research, vol.216, issue.3, pp.291-302, 2014. ,
DOI : 10.1016/j.psychres.2014.02.014
The FDA-NIMH-MATRICS Guidelines for Clinical Trial Design of Cognitive-Enhancing Drugs: What Do We Know 5 Years Later?, Schizophrenia Bulletin, vol.151, issue.1-2, pp.1209-1226, 2011. ,
DOI : 10.1016/j.psychres.2006.10.007
A Summary of the FDA-NIMH-MATRICS Workshop on Clinical Trial Design for Neurocognitive Drugs for Schizophrenia, Schizophrenia Bulletin, vol.31, issue.1, pp.5-19, 2005. ,
DOI : 10.1093/schbul/sbi020
Clinical Trials of Potential Cognitive-Enhancing Drugs in Schizophrenia: What Have We Learned So Far?, Schizophrenia Bulletin, vol.36, issue.2, pp.417-452, 2013. ,
DOI : 10.1038/npp.2010.193
Cognitive deficit awareness in schizophrenia: absent, intact, or somewhere in-between? Cognit Neuropsychiatry, 2014. ,
Measurement Issues in the Use of Cognitive Neuroscience Tasks in Drug Development for Impaired Cognition in Schizophrenia: A Report of the Second Consensus Building Conference of the CNTRICS Initiative, Schizophrenia Bulletin, vol.110, issue.1, pp.613-621, 2008. ,
DOI : 10.1037/0021-843X.110.1.15
Identifying Cognitive Mechanisms Targeted for Treatment Development in Schizophrenia: An Overview of the First Meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative, Biological Psychiatry, vol.64, issue.1, pp.4-10, 2008. ,
DOI : 10.1016/j.biopsych.2008.03.020
Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia II: Developing Imaging Biomarkers to Enhance Treatment Development for Schizophrenia and Related Disorders, Biological Psychiatry, vol.70, issue.1, pp.7-12, 2011. ,
DOI : 10.1016/j.biopsych.2011.01.041
Comparison of psychophysical, electrophysiological, and fMRI assessment of visual contrast responses in patients with schizophrenia, NeuroImage, vol.67, pp.153-62, 2013. ,
DOI : 10.1016/j.neuroimage.2012.11.019
A meta-analysis of fMRI studies in healthy relatives of patients with schizophrenia, Australian & New Zealand Journal of Psychiatry, vol.153, issue.10, 2014. ,
DOI : 10.3389/fpsyt.2013.00150
Diagnostik und Therapiemonitoring kognitiver Defizite schizophrener Patienten mittels funktioneller MRT. Radiol, Feb, vol.50, issue.2, pp.131-136, 2010. ,
Novel antipsychotics and negative symptoms, International Clinical Psychopharmacology, vol.13, pp.43-47, 1998. ,
DOI : 10.1097/00004850-199803003-00008
Defining and measuring negative symptoms of schizophrenia in clinical trials, European Neuropsychopharmacology, vol.24, issue.5, pp.737-780, 2014. ,
DOI : 10.1016/j.euroneuro.2013.10.016
The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia, Schizophrenia Bulletin, vol.13, issue.2, pp.261-76, 1987. ,
DOI : 10.1093/schbul/13.2.261
The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations, Br J Psychiatry, issue.7, pp.49-58, 1989. ,
The negative symptom assessment: a new instrument to assess negative symptoms of schizophrenia, Psychopharmacol Bull, vol.25, issue.2, pp.159-63, 1989. ,
Validation of a 4-item Negative Symptom Assessment (NSA-4): a short, practical clinical tool for the assessment of negative symptoms in schizophrenia, International Journal of Methods in Psychiatric Research, vol.56, issue.2, pp.31-37, 2011. ,
DOI : 10.1016/S0920-9964(01)00161-X
The Brief Negative Symptom Scale: Psychometric Properties. Schizophr Bull, pp.300-305, 2011. ,
DOI : 10.1037/t28694-000
The Clinical Assessment Interview for Negative Symptoms (CAINS): Final Development and Validation, American Journal of Psychiatry, vol.170, issue.2, p.165 ,
DOI : 10.1176/appi.ajp.2012.12010109
The NIMH-MATRICS Consensus Statement on Negative Symptoms, Schizophrenia Bulletin, vol.30, issue.2, pp.214-223, 2006. ,
DOI : 10.1016/0165-1781(89)90153-4
Methodological Issues in Negative Symptom Trials, Schizophrenia Bulletin, vol.32, issue.2, pp.250-254, 2011. ,
DOI : 10.1093/schbul/sbj013
Negative Symptoms in Schizophrenia: Comments From a Clinical Psychology Perspective, Schizophrenia Bulletin, vol.155, issue.3, pp.231-234, 2006. ,
DOI : 10.1176/ajp.155.3.350